"Indoco Remedies received final approval of its ANDA (Abbreviated New Drug Application) for Febuxostat tablets 40 mg and 80 mg, which is therapeutically equivalent to the Reference Listed Drug (RLD), viz, Uloric Tablets 40 mg and 80 mg of Takeda Pharmaceuticals USA, Inc," the company said in a filing to the BSE.Indoco gets USFDA nod for Febuxostat tablets
"Indoco Remedies received final approval of its ANDA (Abbreviated New Drug Application) for Febuxostat tablets 40 mg and 80 mg, which is therapeutically equivalent to the Reference Listed Drug (RLD), viz, Uloric Tablets 40 mg and 80 mg of Takeda Pharmaceuticals USA, Inc," the company said in a filing to the BSE.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment